Stomach cancer hope: triple therapy may boost tumor clearance before surgery
NCT ID NCT07408609
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests whether adding low-dose radiotherapy and the immunotherapy drug tislelizumab to standard chemotherapy can improve outcomes for people with locally advanced stomach or gastroesophageal junction cancer. About 114 participants will be randomly assigned to receive either the combination therapy or chemotherapy alone before surgery. The main goal is to see if the combination leads to a higher rate of complete tumor disappearance (pathological complete response) at the time of surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tislelizumab (an immunotherapy drug), oxaliplatin, capecitabine, and low-dose radiation
What this could lead to
If successful, this combination could improve the chance of eliminating all visible cancer before surgery, potentially leading to better long-term outcomes for patients with locally advanced gastric cancer.
What could go wrong
This is a small, early-phase (phase II) trial, so results may not be definitive. Adding immunotherapy and radiation to chemotherapy may increase side effects, and the approach might not work better than chemotherapy alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.